Ginsenoside Rg1 API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ginsenoside Rg1 API 22427-39-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ginsenoside Rg1. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ginsenoside Rg1
- Synonyms:
- Ginsenoside A2 , Panaxoside A , Sanchinoside C1
- Cas Number:
- 22427-39-0
- DrugBank number:
- DB06750
- Unique Ingredient Identifier:
- PJ788634QY
General Description:
Ginsenoside Rg1, identified by CAS number 22427-39-0, is a notable compound with significant therapeutic applications. Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng). Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.
Metabolism:
Ginsenoside Rg1 undergoes metabolic processing primarily in: M1 (20- O -β- D -glucopyranosyl-20( S )- protopanaxadiol ) is a ppd-type monoglucoside ginsenoside metabolized by intestinal bacteria in humans. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Classification:
Ginsenoside Rg1 belongs to the class of organic compounds known as triterpene saponins. These are glycosylated derivatives of triterpene sapogenins. The sapogenin moiety backbone is usually based on the oleanane, ursane, taraxastane, bauerane, lanostane, lupeol, lupane, dammarane, cycloartane, friedelane, hopane, 9b,19-cyclo-lanostane, cycloartane, or cycloartanol skeleton, classified under the direct parent group Triterpene saponins. This compound is a part of the Organic compounds, falling under the Lipids and lipid-like molecules superclass, and categorized within the Prenol lipids class, specifically within the Terpene glycosides subclass.
Categories:
Ginsenoside Rg1 is categorized under the following therapeutic classes: Carbohydrates, Central Nervous System Agents, Glycosides, Panax, Saponins, Terpenes, Triterpenes. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Ginsenoside Rg1 is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
